Since the discovery of insulin almost 100 years ago, there has been no novel therapy introduced for Type 1 diabetes. That could change in the coming months, however, if the […]
read more
Set Your Sights On These Eye Healthcare Stocks
“If you are willing to tolerate the slight risk posed by healthcare stocks, you might emerge from this period of market undulation with a sizable profit,” advises the author of […]
read more
3 High Risk/High Reward Coronavirus Stocks For Aggressive Investors
The three small-cap biotech stocks highlighted in today’s article have seen their stocks soar this year – from 380% up to 2600% – on their respective plans to develop COVID-19 […]
read more
As Day Trading Explodes, 5 Stocks For Day Traders To Consider Right Now
“Whether they’re simply folks finding more free time during working hours or someone finally willing to try out the stock market with a stimulus (or unemployment) check, there’s been an […]
read more
These U.S. Pot Stocks Could Double
U.S. pot stocks have done well since the stock market’s March bottom – and with voters in New Jersey and Arizona likely to support recreational pot sales in those states […]
read more
2 Truly Transformative Tech Trends To Focus On – And 2 Stocks Set To Profit From Those Trends
When it comes to technology trends, the cloud computing trend that generated so much success for the largest tech companies can no longer really be considered new and transformative. So […]
read more
3 Biotech Penny Stocks To Watch Right Now
“When you throw penny stocks and biotech stocks together…risk and volatility are magnified,” notes the author of today’s article. So, with this in mind, which biotech penny stocks may be […]
read more
Which Frontrunner’s COVID-19 Vaccine Candidate May Hold The Most Promise – And Why?
Of four frontrunners in the race for a vaccine for COVID-19 – Moderna, Pfizer and BioNTech, Inovio Pharmaceuticals, and AstraZeneca – is there any indication at this point whose vaccine […]
read more
4 Small-Caps Set To Surge
Long periods of underperformance by an asset class have historically been followed by extended periods of outperformance, so when it comes to finding the next big stock winners, investors may […]
read more
After An Incredible 4748% Surge, Still Plenty Of Room To Run For Vaxart?
Shares of vaccine specialist Vaxart have exploded an astonishing 4748% so far this year, as investors have piled into the company on the hopes that it – and its “one-of-its-kind” […]
read more